We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


MDI and Launch Diagnostics Announce Distribution Agreement and Launch of Detect-Ready™ MRSA Assay

Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of " MDI and Launch Diagnostics Announce Distribution Agreement and Launch of Detect-Ready™ MRSA Assay"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Molecular Detection Inc. (MDI), a company developing Detect-Ready™ assays designed to increase the speed and accuracy of infectious disease diagnosis, and Launch Diagnostics Ltd. announced an exclusive distribution agreement for MDI’s Detect-Ready MRSA assay in the UK, France and Republic of Ireland.

They also announced the commercial launch of the Detect-Ready MRSA assay, which offers healthcare providers a high performance MRSA screening test with a combination of speed and flexibility, in the UK and the Republic of Ireland.

“Our innovative Detect-Ready MRSA assay offers important advantages to the rapidly growing market for MRSA screening, and we are delighted to finalize this distribution agreement with Launch Diagnostics for the important British, Irish and French markets,” said Todd Wallach, CEO of MDI. “Our goal was to identify a respected independent distributor with a strong track record in the successful introduction of innovative healthcare products, and we have found such a partner in Launch Diagnostics, which has established relationships at potential major accounts and ongoing responsibility for one of the key analytic platforms that runs our assay. We intend to continue working closely with the company to ensure a successful Detect-Ready MRSA assay launch in the high profile UK market, which is an acknowledged leader in establishing successful MRSA control programs.”

Drug-resistant, potentially deadly MRSA infections are a growing problem in healthcare facilities around the world. The Detect-Ready MRSA kit is a qualitative real-time PCR (rt-PCR) in vitro diagnostic test for the direct detection of MRSA nasal colonization to aid in the prevention and control of MRSA infections in hospitals and other healthcare settings.

The proprietary technology in the Detect-Ready kits provides a differential diagnosis engine that produces highly accurate results, minimizing the false positives and false negatives experienced with other diagnostic screening kits. Samples for testing are simple to obtain using nasal swabs and the assay’s ready-to-use pre-mixed reagents require only the addition of patient sample to run the test, which provides results in less than three hours.

Unlike other testing products that require special handling, Detect-Ready kits are off-the-shelf room temperature-stabilized and require no refrigeration. Detect-Ready kits are compatible with multiple rt-PCR platforms currently found in clinical laboratories, including the Roche LightCycler®, Qiagen RotorGene® and Cepheid SmartCycler®. The flexibility to leverage existing infrastructure and equipment to run Detect-Ready assays eliminates the need for additional hospital capital investment.

“Launch Diagnostics has been providing high quality marketing and distribution support to leading in vitro diagnostics manufacturers for 20 years, and we are very pleased to have been selected to introduce the Detect-Ready MRSA assay into a number of key European markets,” said John Twycross, Joint Managing Director, Launch Diagnostics. “MRSA infections are a major problem in health facilities worldwide and the markets we serve, such as the UK, are introducing major proactive MRSA control programmes. With its unmatched combination of accuracy, speed, versatility and cost-effectiveness, we believe the Detect-Ready MRSA assay addresses an important unmet need. We look forward to bringing our expertise, infrastructure and commitment to customer service to help ensure its commercial success.”